You are here

  • Home
  • Archive
  • Volume 10, Issue 11
  • Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis

Article metrics

Article menu

This article has a correction. Please see:

Immunotherapy biomarkers
Original research
Nivolumab serum concentration in metastatic melanoma patients could be related to outcome and enhanced immune activity: a gene profiling retrospective analysis

 

Online download statistics by month:

Online download statistics by month: November 2022 to September 2025

AbstractFullPdf
Nov 202223724182
Dec 202213013041
Jan 202314514636
Feb 202310110245
Mar 2023606120
Apr 2023515121
May 2023464818
Jun 2023454513
Jul 2023606128
Aug 2023616212
Sep 2023383927
Oct 202330307
Nov 2023343410
Dec 2023303011
Jan 2024384032
Feb 2024252517
Mar 2024424230
Apr 2024292915
May 2024282815
Jun 2024313017
Jul 2024333518
Aug 202426247
Sep 2024222211
Oct 2024333317
Nov 202427309
Dec 202430319
Jan 2025474916
Feb 202511511512
Mar 202536367
Apr 2025616130
May 2025515236
Jun 2025222214
Jul 2025110
Sep 2025110
Total17661786683